crypto market coins

Trump said that individuals or companies that invest more than $1 billion in the United States will get accelerated approval. US President-elect Trump wrote in a post on his social media Truth Social on Tuesday: "Any individual or company that invests more than $1 billion in the United States will get comprehensive and accelerated approval and permission, including but not limited to all environmental approvals." This is the latest sign that Trump intends to relax the supervision of federal agencies and attract more foreign investment during his second term.Jin Guanping, Economic Daily: Implement more active and promising macro policies. The article points out that the Political Bureau of the Communist Party of China (CPC) Central Committee held a meeting on December 9 to analyze and study the economic work in 2025, and put forward "implement more active and promising macro policies" and "strengthen unconventional countercyclical adjustment" in view of the macro policy orientation next year, and clearly implement more active fiscal policies and moderately loose monetary policies. This important deployment has released a clear signal of strengthening macro-control and strong and steady growth. Implementing a "more active" fiscal policy means increasing fiscal countercyclical adjustment and improving the effectiveness of fiscal policy while maintaining policy stability and continuity. "Moderately loose" means that monetary policy will better reflect the supportive stance and orientation, maintain a reasonable and sufficient liquidity, and further reduce the comprehensive financing costs of enterprises and residents.Eight-day four-board three-dimensional communication: the company's operation is normal, and the internal and external operating environment has not changed significantly. On December 9, December 10 and December 11, 2024, the company's closing price increase deviated by more than 20% for three consecutive trading days, which belongs to the abnormal fluctuation of stock trading. The company's operation is normal, and the internal and external operating environment has not changed significantly. The Company has no other circumstances that violate the provisions on fair disclosure of information.

The Bank of Korea increased its liquidity to try to calm the market sentiment, and the Bank of Korea increased its capital injection into the financial market, promising to provide "unlimited liquidity" after the political turmoil intensified. According to the website of the Bank of Korea, the liquidity increased by 14.1 trillion won ($9.8 billion) through repurchase operations last week. The scale of such operations was 18.5 trillion won in November and only 1.5 trillion won in October.Kei Ma quit Xiaomi Home Technology Co., Ltd., and Tianyancha App showed that recently, Xiaomi Home Technology Co., Ltd. underwent industrial and commercial changes, and Kei Ma stepped down as the legal representative and manager. As Peng took over, Lei Jun was changed from an executive director to a director. Xiaomi Home Technology Co., Ltd. was established in January 2017 with a registered capital of RMB 80 million. Its business scope includes communication equipment sales, computer software and hardware and auxiliary equipment wholesale, computer software and hardware and auxiliary equipment retail, shoes and hats wholesale, motorcycles and spare parts wholesale, etc. It is wholly owned by Xiaomi Communication Technology Co., Ltd. According to media reports, recently, Kei Ma, vice president of Xiaomi Group, has left his post, and the news has aroused many concerns.In November, the scale of wealth management exceeded expectations, and the scale of 14 wealth management companies increased by over 420 billion yuan. In November, the product scale of wealth management companies ushered in a general increase. According to the obtained data, in November, there were 6 state-owned wealth management companies and 8 joint-stock wealth management companies (CMB, Xingyin, Everbright, Xinyin, Ping 'an, Huaxia, Puyin and Minsheng), totaling 14 wealth management companies, with a survival scale of nearly 22.6 trillion yuan, an increase of more than 420 billion yuan compared with October, and the growth rate was slightly lower than the impact of capital backflow in October. (21st century business herald)

Hengrui Pharma: HRS-4729 injection was approved for clinical trial. Hengrui Pharma announced that the company and its subsidiary Fujian Sheng Di Pharmaceutical Co., Ltd. received the Notice of Approval for Clinical Trial of HRS-4729 injection approved and issued by National Medical Products Administration. The drug is a polypeptide drug independently developed, and it is a GLP-1R/GIPR/GCGR triple agonist, which is suitable for obese or overweight patients. Up to now, HRS-4729 injection has invested about 19.56 million yuan in research and development.Japanese manufacturers' confidence index turned negative to the central bank's forecast in December. A short-term survey in Reuters, Japan, found that Japanese manufacturers' business confidence deteriorated further in December due to concerns about US protectionist policies. The survey of 505 large Japanese non-financial enterprises showed that manufacturers' confidence index fell from 5 in November to -1 in December, which was the first time since last February, and the number of pessimists exceeded optimists for the first time in 10 months. The loss of business confidence may cast a shadow over the Bank of Japan's forecast. The Bank of Japan had previously predicted that a steady recovery driven by rising wages and consumption would help inflation reach the 2% target in a sustainable way and justify further interest rate hikes. Many manufacturing industries have reported that business confidence has declined. Among electronic machinery manufacturers, steel and non-ferrous metal manufacturers, pessimists far exceed optimists.Hengrui Pharma: HRS-4729 injection was approved for clinical trial. Hengrui Pharma announced that the company and its subsidiary Fujian Sheng Di Pharmaceutical Co., Ltd. received the Notice of Approval for Clinical Trial of HRS-4729 injection approved and issued by National Medical Products Administration. The drug is a polypeptide drug independently developed, and it is a GLP-1R/GIPR/GCGR triple agonist, which is suitable for obese or overweight patients. Up to now, HRS-4729 injection has invested about 19.56 million yuan in research and development.